AtaiBeckley News and Activities

AtaiBeckley is a company listed under the stock ticker ATAI (DE).

AtaiBeckley has a direct presence in 2 countries.

View the org chart displaying its 40 main executives

Most searched biographies at AtaiBeckley

• Srinivas Rao, Chief Executive Officer
• Rob Hershberg, Director
• Christian Angermayer, Chairman of the Board

Popular executive movements at AtaiBeckley

• Anne Johnson who was Chief Financial Officer, becomes Chief Accounting Officer  (posted on February 19 2026).
• Michael Faerm has joined the company as Chief Financial Officer  (posted on February 19 2026).

Create your alert
to follow the executive moves at AtaiBeckley.

AtaiBeckley has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by AtaiBeckley

• AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations | AtaiBeckley Inc.
• AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 | AtaiBeckley Inc.
• AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update | AtaiBeckley Inc.
• AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research | AtaiBeckley Inc.
• AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder | AtaiBeckley Inc.
• AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences | AtaiBeckley Inc.
• Press releases | AtaiBeckley Inc.
• AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs | AtaiBeckley Inc.
• AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst | AtaiBeckley Inc.
• BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation | AtaiBeckley Inc.
• View more press releases Close

Social media about AtaiBeckley

• AtaiBeckley on Wikipedia, Google News & Yahoo Finance
• AtaiBeckley on LinkedIn, X (Twitter) & YouTube